Drug Trial Radar · NCT07412080
EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia
Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jul 1, 2025
Primary completion
Dec 12, 2025
Study completion Dec 12, 2025
Sponsor
- Lead sponsor
- Eddingpharm (Zhuhai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions. This is the first in human study of EDP167 in health volunteers and subjects with mild dyslipidemia to evaluate the safety and PK/PD profiles of EDP167.
Conditions
- Healthy Adult Male and Female Volunteers
- Mild Dyslipidemia
Interventions
EDP167Drug
EDP167 sc injection
PlaceboDrug
Sterile normal saline (0.9% NaCl) sc injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of a single subcutaneous injection of EDP167 in adult subjects.Time frame: Up to 85 days post-dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.